Abstract 21P
Background
Due to the limited accessibility of trastuzumab, the majority of Her2 positive breast cancer patients are treated mainly with systemic chemotherapy in Myanmar. This study aimed to find out the clinical outcome of treatment without trastuzumab for Her2 positive breast cancer patients.
Methods
A retrospective observational study of total 156 Her2 positive breast cancer patients not receiving anti-her2 therapy who diagnosed between January 2007 and December 2016 in two private oncology centers in Yangon, Myanmar.
Results
In this study, median age of patients was 52 years (25yrs-87yrs). Majority (80%, n = 126) were in early stage. Regarding treatment pattern, 99% of patients underwent either simple or total mastectomy and only 1% was done breast conserving surgery. Anthracycline containing regimes (AC-T or FAC) were given in 99% of patients. Among them, 26% (n = 40) took additional maintenance chemotherapy with oral cyclophosphamide and methotrexate for 3 to 6 months after conventional chemotherapy. After a median follow up of 40 months (8-120), 80% of patients achieved complete response. The median disease free period was 34 months and 3 year invasive disease free survival was 79%. The relapse rate was 17.3%. Lymph nodes (23%) and liver metastases (23%) were the first site of recurrence in relapsed patients. Furthermore, 92% had no recurrence among those received maintenance chemotherapy.
Conclusions
Anthracycline based systemic chemotherapy without anti Her2 therapy showed good clinical outcome in Her2 positive breast cancer patients in real clinical practice in Myanmar.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Medical oncology academic group.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
28P - Accuracy of core biopsy in predicting pathologic complete response in the breast in patients with complete/near complete clinical and radiological response (Complete Responders in the Breast – CRBr): A feasibility study
Presenter: Nisha Hariharan
Session: Poster display session
Resources:
Abstract
29P - Tumour response to neoadjuvant chemotherapy in breast cancer: Routine pathologic markers improve the predictive power of a cell-loss metric based on release of thymidine kinase 1 into blood
Presenter: Bernhard Tribukait
Session: Poster display session
Resources:
Abstract
30P - Comparison of metabolic changes between neoadjuvant chemotherapy and neoadjuvant endocrine therapy in premenopausal women with ER positive, HER2 negative breast cancer
Presenter: Ho-hyun Ryu
Session: Poster display session
Resources:
Abstract
31P - Circulating miR-155 as a potential therapeutic monitoring marker in breast cancer
Presenter: Sumadi Lukman Anwar
Session: Poster display session
Resources:
Abstract
32P - Profile of breast cancer epidemiology in Sanglah General Hospital, Denpasar, Bali from 2012 to 2019
Presenter: Citra Aryanti
Session: Poster display session
Resources:
Abstract
33P - Contrast enhanced chest CT in patients with breast cancer: Comprehensive imaging analysis and correlation with biological markers
Presenter: Bo Hwa Choi
Session: Poster display session
Resources:
Abstract
34P - Verification of metabolic regulatory mechanisms in androgen receptor-positive triple negative breast cancer
Presenter: Yuka Asano
Session: Poster display session
Resources:
Abstract
35TiP - Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in pre-/perimenopausal patients with HR+, HER2– inoperable locally advanced breast cancer (ABC): RIGHT choice study
Presenter: Yen-Shen Lu
Session: Poster display session
Resources:
Abstract
36TiP - A prospective study to assess response to neoadjuvant hormonal therapy in postmenopausal women with hormone-receptor positive breast cancer at a regional cancer centre in South India
Presenter: Shina Goyal
Session: Poster display session
Resources:
Abstract
41P - Clinical verification on the relationship between serum lipid metabolism and the immune microenvironment in breast cancer patients
Presenter: Wataru Goto
Session: Poster display session
Resources:
Abstract